AZN vs. REGN: AstraZeneca vs. Regeneron Pharmaceuticals Stock Comparison
How do AstraZeneca (AZN) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AstraZeneca (AZN) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while REGN is classified in Biotechnology.
Regeneron Pharmaceuticals (REGN) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AZN | REGN |
|---|---|---|
| Name | AstraZeneca PLC American Depositary Shares | Regeneron Pharmaceuticals, Inc. |
| Country/Region | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Biotechnology |
| GICS Sub-Industry | Pharmaceuticals | Biotechnology |
| Market Capitalization | 289.14 billion USD | 93.55 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 12, 1993 | April 2, 1991 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AZN | REGN |
|---|---|---|
| Total Return (1Y) | 12.64% | 40.87% |
| Total Return (3Y, Annualized) | 15.75% | 5.15% |
| Total Return (5Y, Annualized) | 10.63% | 8.58% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AZN | REGN |
|---|---|---|
| Volatility (1Y, Annualized) | 28.21% | 34.08% |
| Beta (5Y) | 0.22 | 0.10 |
| Max Drawdown (5Y) | -27.87% | -59.69% |
| Avg. Volume (3M) | 3.14M | 772.95K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AZN | REGN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.30 | 1.07 |
| Sortino Ratio (1Y) | 0.44 | 1.70 |
Profitability
ROE (TTM)
Both AstraZeneca (AZN) at 22.57% and Regeneron Pharmaceuticals (REGN) at 14.95% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.57%
- Max
- 109.18%
- AZN
- 22.57%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.95%
- Max
- 109.18%
- REGN
- 14.95%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and AstraZeneca (AZN) at 17.68% also retains a top-quartile share.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.68%
- Max
- 18.05%
- AZN
- 17.68%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.51%
- REGN
- 28.51%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AstraZeneca (AZN) at 29.57% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.57%
- Max
- 83.12%
- AZN
- 29.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.46%
- Max
- 83.12%
- REGN
- 40.46%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AZN | REGN |
|---|---|---|
| ROE (TTM) | 22.57% | 14.95% |
| ROA (TTM) | 8.59% | 7.59% |
| Net Margin (TTM) | 17.68% | 28.51% |
| Operating Margin (TTM) | 29.57% | 40.46% |
| Gross Margin (TTM) | 81.78% | 46.73% |
Growth
Revenue Growth
Both AstraZeneca (AZN) at 8.63% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both AstraZeneca (AZN) at 45.33% and Regeneron Pharmaceuticals (REGN) at 8.19% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | AZN | REGN |
|---|---|---|
| Revenue Growth (YoY) | 8.63% | 0.99% |
| Revenue Growth (3Y CAGR) | 9.82% | 5.62% |
| EPS Growth (YoY) | 45.33% | 8.19% |
| EPS Growth (3Y CAGR) | 45.80% | 2.77% |
Financial Strength
Current Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while AstraZeneca (AZN) at 1.01 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AZN.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AZN
- 1.01
- Min
- 0.10
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- REGN
- 3.35
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Regeneron Pharmaceuticals (REGN) at 0.08 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.66
- Max
- 1.42
- AZN
- 0.66
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.08
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- REGN
- 0.08
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AZN | REGN |
|---|---|---|
| Current Ratio (MRQ) | 1.01 | 3.35 |
| Debt / Equity (MRQ) | 0.66 | 0.08 |
| Net Debt / EBITDA | 1.23 | -1.17 |
Dividends
Dividend Yield (TTM)
Both AstraZeneca (AZN) at 1.73% and Regeneron Pharmaceuticals (REGN) at 0.41% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73%
- AZN
- 1.73%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41%
- REGN
- 0.41%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both AstraZeneca (AZN) at 45.38% and Regeneron Pharmaceuticals (REGN) at 8.18% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.38%
- AZN
- 45.38%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.18%
- REGN
- 8.18%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AZN | REGN |
|---|---|---|
| Dividend Yield (TTM) | 1.73% | 0.41% |
| Dividend Payout Ratio (TTM) | 45.38% | 8.18% |
Valuation
P/E Ratio (TTM)
Both AstraZeneca (AZN) at 26.37 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.37
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- AZN
- 26.37
- Q1
- 13.30
- Min
- 0.07
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.99
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- REGN
- 19.99
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both AstraZeneca (AZN) at 4.63 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AZN
- 4.63
- Q1
- 3.01
- Min
- 0.01
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.54
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- REGN
- 5.54
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both AstraZeneca (AZN) at 5.59 and Regeneron Pharmaceuticals (REGN) at 2.71 are valued close to their industries’ norm against book — neither stands out from peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.59
- Max
- 13.53
- Q3
- 6.54
- AZN
- 5.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- REGN
- 2.71
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AZN | REGN |
|---|---|---|
| P/E Ratio (TTM) | 26.37 | 19.99 |
| P/S Ratio (TTM) | 4.63 | 5.54 |
| P/B Ratio (MRQ) | 5.59 | 2.71 |
| Free Cash Flow Yield (TTM) | 1.95% | 2.76% |